Related Experiment Video
Updated: Apr 6, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Impact of sensitivity difference between two widely used HDV RNA quantification assays on the management of
Valérian Delagarde1, Athenais Gerber1, Samira Dziri2
1AP-HP, Hôpital Avicenne, Service de microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Bobigny, France; Inserm U955, équipe 18, Université Paris-Est, Créteil, France.
Background & Aim:
Accurate hepatitis Delta virus (HDV) RNA quantification is crucial for diagnosing and managing HDV infection, especially for low viral loads. Here, we evaluate the sensitivity of two commonly used HDV RNA quantification assays - the new EurobioPlex EBX071 assay and the RoboGene 2.0 assay - in real-life conditions, and assess the impact on the management of HDV patients treated with Bulevirtide.
Methods:
Frozen plasma samples that had already been quantified using the EBX071 assay were collected from three hospital laboratories, focusing specifically on low-level replicating samples. All samples were quantified using the RoboGene 2.0 assay, and sequential RNA quantifications were performed on 48 patients undergoing anti-HDV treatment with longitudinal HDV RNA testing.
Results:
A total of 190 samples were included in the comparative analysis. The quantification results obtained using EBX071 and RoboGene 2.0 assays were concordant for the majority of samples. However, the RoboGene 2.0 assay was found to be more sensitive for a small proportion of patients with very low viremia (5-20 IU/mL).
Conclusion:
The two HDV RNA quantification assays are generally equivalent, although RoboGene 2.0 is slightly more sensitive. Given the long duration of current treatments, however this difference should have minimal implications for the clinical management of chronic HDV patients.
